News

Proscia Introduces Enhanced Concentriq AP with Multi-AI Workflows for Pathology

by Roman Kasianov   •  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

Proscia, a provider of AI-powered pathology solutions for precision medicine, has announced an update to its Concentriq AP platform. The latest version introduces multi-AI workflows, enabling pathologists to simultaneously view results from multiple AI applications within Proscia’s precision medicine AI portfolio.

This development marks an advancement in the integration of AI in pathology, particularly in the diagnosis and understanding of major cancers such as breast, colon, gastric, lung, and prostate cancers.

The Concentriq AP platform is a cloud-based workflow solution designed to enhance efficiency and confidence in digital pathology, catering to large global laboratory networks. The new multi-AI workflows feature allows pathologists to view a comprehensive set of AI-generated insights on a single interface, removing the need to analyze individual AI solutions separately. This approach is expected to improve diagnostic accuracy and operational efficiency.

Concentriq AP tool; Image source: Proscia.com

Key features of the updated Concentriq AP include:

  • DICOM Image Integration: The platform now supports the viewing and ingestion of DICOM images, promoting IT efficiency and enhanced interoperability.
  • API Enhancements: Updated APIs facilitate the seamless integration of additional third-party and custom AI applications into Concentriq AP’s multi-AI workflows.
  • Multilingual Support: Full support for 13 languages aligns with Proscia’s expanding global customer base.
  • Performance Improvements: Enhancements in performance, scalability, and usability optimize the platform for achieving complete digitization of pathology workflows.

Derek C. Welch, M.D., Chief Medical Officer and Executive Vice-President at PathGroup, emphasized the practical impact of AI in pathology, stating:

“Concentriq AP now enables laboratories to realize the collective value of a broad AI portfolio while providing a robust solution for their routine operations.”

Sowmya Ballakur, Proscia’s Senior Vice President of Product, highlighted the collaborative development of the new Concentriq AP version with customers, aiming to support the scalability and innovation needed for precision medicine in pathology.

This update follows recent developments from Proscia, including a study conducted with Quest Diagnostics on the impact of AI-enabled workflows and a partnership with Nucleai to incorporate AI predictive biomarkers into its precision medicine portfolio. The company has also expanded its clinical customer base by over 100% in the past year.

See also: First-of-its-kind AI-based Diagnostics Solutions Approved in Europe

For more information on the new release of Concentriq AP, Proscia will host a webinar titled "Concentriq AP: A New Era Of AI In Pathology" on September 17, 2024.

Proscia continues to lead the transformation of digital pathology with its enterprise platform and AI applications, striving to enhance research, improve patient outcomes, and advance precision medicine.

Title image source: Proscia.com

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook